lintuzumab-ac225
actinium
['myeloid', 'lintuzumab']
today from 9 am -12:30 pm et at #aacr23 our first poster will be available in section 40: targeting myeloid-derived suppressor cells with actinium-225 lintuzumab, a cd33 antibody radioconjugate to enhance antitumor immunity. more details here: $atnm 
Actinium is developing innovative targeted radioimmunotherapies for the treatment of advanced cancers. Currently investigating therapies in #AML #BMT $ATNM